buyModerate cluster of 2
Broadwood Partners, L.p. bought $11M of IMDX
owner at Oncocyte Corp. 5,165,695 shares at an average of $2.05, traded Feb 6, 2025, filed Feb 10, 2025.
Conviction score
50Value
$11M
5,165,695 shares
Holdings after
11,410,100
+83% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$10.6M at market
- +10Relative to holdingsHoldings up 83%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000919574-25-000922, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 6, 2025 | POpen-market purchase Common Stock, no par value | +660,207 | $2.05 | $1.4M | 6,904,612 | Feb 10, 2025 |
| Feb 6, 2025 | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 6,904,612 | Feb 10, 2025 |
| Feb 6, 2025 | POpen-market purchase Common Stock, no par value | +4,505,488 | $2.05 | $9.2M | 11,410,100 | Feb 10, 2025 |
| Feb 6, 2025 | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 11,410,100 | Feb 10, 2025 |
Related signals
Other insiders at Oncocyte Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | Oncocyte Corp | Andrea S. James Chief Financial Officer | $200k 97,561 shares | +182% | |
| 30Weak | Oncocyte Corp | Patrick W Smith owner | $192k 90,219 shares | +5% | |
| 31Weak | Oncocyte Corp | Andrew Arno director | $26k 12,500 shares | +18% | |
| 38Weak | IMDXbuy Oncocyte Corp | Andrea S. James Chief Financial Officer | $46k 20,000 shares | +59% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.